The future of cancer treatment relies on patient enrollment in clinical trials. In a recent Chicago Tribune article, a patient story is highlighted to illustrate the important role clinical trials play in cancer treatment, not only in [...]
At the recent American Society of American Oncology Meeting (ASCO), Dr. George Demetri, Director of the Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, presented results from a collaborative trial that indicates in [...]
A recent article from Cancer Research UK discusses immunotherapy, and the attention its role in the future of cancer treatment may play. In response to the interest in immunotherapy at the 50th Annual Meeting of [...]
Research!America and the Pancreatic Cancer Action Network held a meeting in New York this year to discuss ways to restructure clinical trials to find a cure for cancer.
A recent clinical trial found that 1 year of adjuvant imatinib was able to increase recurrence-free survival. Keep reading to learn more.
Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.
Prior to 2000, surgery was the only known effective treatment for advanced GIST.
One of the frequently asked questions from the GIST Community is “Why are there some GIST patients who do not take any medication to treat GIST?”
From October 30th to November 2nd the Life Raft Group staff members attended the annual Connective Tissue Oncology Society (CTOS) Meeting in NYC.
ARIAD has announced that their ponatinib (Iclusig) trial, which some GIST patients are participating in, has paused new enrollment based on consultations with the FDA regarding patients who experienced particular vascular events. Subject to agreement with [...]
